Skip Nav

Contact Us

Chondrosarcoma CS Foundation, Inc.

Thank you for your interest in our company. Complete the form below to send us an email, or simply give us a call. We're looking forward to working with you.

  • 301-352-3042

    Reaching Out for Support for Chondrosarcoma Awareness Day: February 6, 2021

    We are $167 away from reaching our goal to hire a Marketing / Public Relations expert to help us with broadcast media and social media getting the word out about Chondrosarcoma Awareness Day. The event will take place on February 6 in honor of...

    Read Article

    Holiday Letter from the Snyder Family

    >  > Snyder Family Holiday Letter 2020 > > > Merry Christmas and Happy Holidays from the Snyder family in Albuquerque, New Mexico! Like you and yours, we’ve had a year at Casa Del Snyder where the only constants has been the...

    Read Article

    Tibsovo: Ivosidenib Generates Interest in the Business World

    Agios to Sell Cancer Portfolio to Servier for $1.8 Billion By Emma Court December 21, 2020, 7:00 AM EST Updated on December 21, 2020, 10:18 AM EST Agios Pharmaceuticals Inc. said it agreed to sell its portfolio of oncology drugs to Servier...

    Read Article

    Help Us Get The Word Out: February 6 is Chondrosarcoma Awareness Day

    Read Article

    Virtual Dialogue: Straight Talk About Chondrosarcoma Videos Are Posted On-line: csfshayna.org

    On November 17, 2020 the Chondrosarcoma CS Foundation, Inc. held its first International Virtual Dialogue entitled: Straight Talk About Chondrosarcoma. There were 109 registrations and at one time we had over 80 participants attend the Virtual...

    Read Article

    Message from A CS Warrior: David Bowles

    Hello fellow warriors....well some good news for all of us: I spoke today via video with a doc whose advice I get every 3 months when my CT scans are done, Jonathan Trent MD, Ph.D. (how's that for qualified??) He runs a clinical trial for CS which...

    Read Article

    CS Patient Response to Dulanermin a Dual Proapoptotic Receptor (DR4/DR5)

    Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist Vivek Subbiah 1, Robert E Brown, Jamie Buryanek, Jonathan Trent, Avi Ashkenazi, Roy Herbst, Razelle...

    Read Article

    New Type of Immunotherapy

    New type of immunotherapy may pave the way for better cancer treatments by Karolinska Institutet From left: First author Silke Eisinger and last author Mikael Karlsson from Karolinska Institutet in Sweden. Credit: Mitch Eisinger Immunotherapy for...

    Read Article